Engflag

Modrenal

Quick links to important sections

Modrenal

Modrenal_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modrenal

What is Modrenal? A Definition and Classification

Property Description
Active ingredient Trilostane
Form Oral capsule (Hard gelatin capsule)
Pharmacological class Adrenal enzyme inhibitor, Adrenocortical suppressant
Origin Synthetic compound
Route of administration Oral

Modrenal is a specific prescription-only medicine that utilizes the active ingredient Trilostane for oral administration in adult patients. It is pharmacologically classified as an adrenocortical suppressant, a specialized drug group centered on regulating the activity of the adrenal cortex. The core action of Trilostane is clinically recognized for its role as a steroid synthesis inhibitor, confirming its design to interfere with the body's natural hormone production.

The primary purpose of the medication is to manage and control health conditions resulting from the adrenal gland's excessive output of certain steroid hormones. By suppressing this overactivity, the drug helps restore systemic hormonal balance, which is vital for physiological function.

Composition, Origin, and Dosage Form

The core component, Trilostane, is a synthetic chemical compound derived from a steroidal precursor, ensuring consistent purity and measurable dosing. The medicine is supplied as an oral capsule, a specific dosage form required for systemic absorption following ingestion. This distinct oral formulation ensures the active ingredient is delivered effectively to the circulatory system to target the adrenal glands.

The Principle of Adrenal Regulation

Modrenal operates on the principle of highly focused enzyme inhibition, a mechanism supported by pharmacological studies. It functions by temporarily blocking a key enzyme, 3beta-hydroxysteroid dehydrogenase, which is essential for the creation of steroid hormones, including cortisol and aldosterone. Research demonstrates that this mechanism blocks the production of adrenal steroids, providing a targeted method to reduce hormone levels in the body. This controlled limitation on hormone production provides a direct means to mitigate the physiological impacts arising from endocrine overproduction.

Regulatory References

  1. Trilostane (Modrastane, Modrenal) - NCI Drug Dictionary

What side effects are possible with Modrenal?

Possible Side Effects and Safety Information

The safety profile of Modrenal (Trilostane) is formally documented in government regulatory labeling, categorizing adverse reactions by frequency and the body system affected. All safety information is based strictly on these official regulatory sources.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions, classified as Common in regulatory documents, include gastrointestinal disturbances such as vomiting and diarrhea, lethargy, and fatigue. Metabolic changes, specifically hyperkalemia (elevated potassium levels), are also commonly noted. Reactions documented with lower frequency may include signs of adrenal insufficiency, muscle tremor, and general skin reactions.

System-Organ Classes and Serious Reactions

Adverse effects are formally grouped into System-Organ Classes, primarily involving Endocrine System Disorders (e.g., adrenal insufficiency) and Gastrointestinal Disorders. The most serious adverse reactions explicitly documented in official labeling include Adrenal Crisis (Acute Addisonian Crisis), which is a severe consequence of low cortisol levels, and rare severe cutaneous reactions like Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Population-Specific Constraints and Patterns

The medicine is formally contraindicated for use in individuals with severe hepatic impairment and during both pregnancy and lactation, as stated in the prescribing information. Regulatory documents also note that signs of adrenal insufficiency are more likely to manifest at the start of treatment or following a dose increase. Furthermore, caution is advised regarding the concomitant use with agents that affect potassium levels, such as certain diuretics or ACE inhibitors, due to the increased regulatory risk of hyperkalemia.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Modrenal (Trilostane) is officially documented to lead to manifestations of severe adrenal insufficiency, known as iatrogenic hypoadrenocorticism. This condition arises from excessive suppression of adrenal steroid hormone production, which is an extreme extension of the drug's intended action.

The documented clinical presentations of overdose include non-specific signs such as lethargy, anorexia, vomiting, and diarrhoea. Physiological findings often include electrolyte imbalances, specifically elevated potassium (hyperkalemia) and reduced sodium (hyponatremia).

Regulators require that individuals seek medical advice immediately upon any confirmed or suspected overdose or accidental ingestion. When an overdose is suspected, the treatment must be withdrawn immediately. Severe outcomes documented in official sources include cardiovascular collapse and the potential for adrenal necrosis or adrenal rupture, classified as life-threatening events.

No specific antidote is known for Trilostane. Management of overdose is symptomatic and supportive, aiming to reverse the state of adrenal insufficiency. Supportive procedures often involve administration of corticosteroids, mineralocorticoids, and necessary fluid therapy under clinical supervision.

Therapeutic Uses of Modrenal

What Modrenal Treats: Main Uses and Benefits

Modrenal is applied across therapeutic domains where additional symptomatic support is needed in conditions characterized by periods of heightened symptoms, specifically those linked to adrenal hormone overproduction. The medication is commonly used to help manage symptoms related to systemic imbalance and heightened physiological activity.

The medication is considered relevant for conditions involving hypercortisolism (Cushing's Syndrome) and mineralocorticoid excess (Primary Aldosteronism), and it is considered relevant in contexts involving hormone-driven manifestations in postmenopausal women. The medication is considered relevant for easing symptom clusters that may become intense or disruptive, particularly symptoms related to systemic imbalance, such as high blood pressure or electrolyte disturbances.

Used in clinical settings that involve acute or unstable symptom patterns, it assists with supporting functional stability during difficult episodes.

Quick Fact: Relief for Endocrine Symptoms
Modrenal is primarily relevant for managing symptoms related to sustained hormonal imbalances, addressing manifestations like systemic strain and metabolic disruption caused by the overproduction of adrenal steroids.

Eligibility and Restrictions for Use

Who Can and Cannot Use Modrenal?

The eligibility for Modrenal (Trilostane) is strictly defined by official regulatory documents, establishing clear boundaries for who may use the medicine and who is absolutely prohibited from treatment. The medicine is primarily intended for use in the adult population, and specific conditions related to a patient’s health status or reproductive status serve as mandatory exclusions.

Absolute Contraindications

Modrenal is contraindicated and must not be used by individuals who meet the following criteria:

  • Hypersensitivity: Patients with a known allergy to Trilostane or any of its excipients.
  • Organ Function: Individuals with a diagnosis of Primary Hepatic Disease or Primary Renal Insufficiency.
  • Reproductive Status: Pregnant or lactating individuals, due to the documented risk of fetal harm.

Restricted and Conditional Use

  • Hematological Status: Use is allowed only under conditions of extreme caution in patients with pre-existing anemia, requiring careful management.
  • Age and Population: Use is generally not established or restricted in the pediatric and low-weight population categories, limiting eligibility to adults.

What should I know about interactions with other medicines?

The official regulatory profile for Trilostane (Modrenal) defines constraints for co-administration based on its pharmacodynamic activity and specific administration requirements.

Interaction Classification Official Restriction
Pharmacodynamic Reinforcement Co-administration is advised against with potassium-sparing diuretics (e.g., Spironolactone).
Use With Caution Combinations with ACE Inhibitors (e.g., Enalapril) and other adrenal suppressants (e.g., Mitotane) require specific management.

Use of Trilostane concurrently with other agents that suppress adrenal function or have aldosterone-lowering effects may lead to additive results. The combination with potassium-sparing diuretics and potassium supplements is officially cautioned against or advised not to be used, due to the potential for potentiating hyperkalemia (elevated serum potassium). Combinations with ACE Inhibitors require caution because they may result in additive aldosterone-lowering effects.

When transitioning from other adrenal suppressants like Mitotane, a mandatory separation window is required. An interval of at least one month must pass between the cessation of Mitotane and the initiation of Trilostane treatment. The drug’s absorption is dependent on food intake, establishing the constraint that the capsule must be administered with food for appropriate systemic delivery. Specific studies on interactions mediated by CYP450 enzyme inhibition or induction are not formally included in regulatory information.

Mechanism of Action

How Modrenal Works

Modrenal's action is fundamentally based on highly specific enzyme inhibition that controls the body's steroid hormone synthesis. The mechanism produces targeted and systemic physiological changes.

Molecular Action: Inhibition of 3beta-HSD

The drug and its active form, 17-Ketotrilostane, work by competitively blocking the essential enzyme 3beta-Hydroxysteroid Dehydrogenase (3beta-HSD) within the adrenal gland cells. This molecular intervention is the initial step in the drug’s cascade, resulting in the interruption of the body's ability to produce key steroid hormones.

Physiological Cascade: Suppression of Cortisol

By inhibiting 3beta-HSD, Trilostane rapidly interrupts the adrenal steroid biosynthesis pathway, leading to the suppression of the synthesis and release of the glucocorticoid hormone Cortisol. The resulting reduction in circulating Cortisol levels produces a state of decreased systemic glucocorticoid concentration.

Regulatory Feedback and Limitations

The systemic drop in Cortisol eliminates the normal negative feedback signal to the pituitary gland, resulting in a compensatory increase in ACTH (Adrenocorticotropic Hormone). This elevated ACTH constantly attempts to stimulate the adrenal gland, which represents a physiological constraint that the mechanism encounters.

Dosage and Administration Information

How Modrenal is Used: Official Administration Guidelines

Modrenal (Trilostane) is administered exclusively via the oral route as a hard gelatin capsule, which is the official dosage form designed for systemic absorption. The official prescribing information outlines specific, mandatory conditions necessary for proper intake and maximizing therapeutic effect.

Administration Requirements

Instruction Official Principle
Route and Form Oral capsule only.
Timing in Relation to Meals Must be administered with a meal or food to ensure the necessary enhancement of systemic absorption.
Physical Handling The capsule must be swallowed whole. It must not be opened, divided, or crushed, as this compromises the intended delivery and handling constraints.

Dosing Schedule and Duration

The therapeutic approach begins with a starting dose, followed by a period of titration where the daily dose is carefully adjusted based on the need to maintain hormonal stability. Modrenal is used in a daily administration pattern; depending on the patient's stability throughout the day, the total dose may be split into divided administration (twice daily) to ensure a more consistent therapeutic effect.

As the medication addresses chronic conditions, Modrenal is intended for long-term therapeutic management rather than short, intermittent courses. Its use is formally indicated for adult patients. Adherence to the administration instruction of taking the capsule with food is central to the overall protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Modrenal

Evidence for use in Hypercortisolism (Cushing's Syndrome)

Research has explored the use of this medicine in adult patients diagnosed with various forms of Hypercortisolism, also known as Cushing's Syndrome. Studies included small clinical investigations, retrospective analyses, and extended single-patient case reports. Researchers primarily monitored outcomes related to systemic or functional imbalance, such as the circulating levels of cortisol and the urinary measurements of related adrenal steroids. Studies reported that research examined the production of cortisol. Regulatory reviews and historical research indicated that findings regarding the influence on cortisol levels were mixed or inconsistent across different studies and patient groups. The evidence base is largely historical.

Evidence for use in Mineralocorticoid Excess (Primary Aldosteronism)

The medicine was evaluated in adult patients with conditions of Mineralocorticoid Excess, specifically Primary Aldosteronism (Conn's Syndrome). Clinical research, including small controlled trials, explored short-term changes and monitored key endocrine markers. The outcomes that research examined included plasma aldosterone concentration (PAC), serum potassium levels, and the monitoring of systemic blood pressure as an associated factor. Trials reported measurements of aldosterone and potassium concentrations that were monitored for changes. The medicine was also observed in historical clinical investigations in the context of studying postmenopausal breast cancer, with studies examining the drug in combination with a corticosteroid.

Long-Term Follow-up and Duration of Evidence

Research exploring short-term symptom changes is available, but long-term outcomes are not fully established across large patient groups. Follow-up durations in key studies were limited to the intermediate term. For Cushing's Syndrome, observational studies research describes follow-up periods extending up to several years in individual case reports. These findings describe group patterns, not personal outcomes, and there is limited information to characterize outcomes beyond the intermediate study periods.

Evidence in Special Study Populations

The available research primarily focuses on adult patient cohorts within the clinical contexts that were studied. Data for certain groups, such as children, pregnant populations, or individuals with severe comorbidities, remain insufficient. Findings were observed in some studies that specifically examined the medicine in patients with a unique form of Cushing's syndrome known as ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH), providing documented evidence for this specific patient subgroup.

Research Gaps and Areas of Uncertainty

Key limitations include that sample sizes were modest in the primary clinical investigations. Comparative evidence that fully contrasts this medicine against current therapeutic standards is lacking. The overall level of certainty remains low, particularly because evidence quality varies across studies, and research provides context but not individual predictions. This evidence highlights what is known—and what is still uncertain. The research base is considered historical, as its authorization for human use was revoked in major territories.

Frequently Asked Questions (FAQ)

Common questions about Modrenal (FAQ)

Q: What is Modrenal used to treat?

Official studies have examined Modrenal for use in managing health conditions caused by the excessive output of adrenal steroid hormones, such as Hypercortisolism (Cushing's Syndrome) and Mineralocorticoid Excess (Primary Aldosteronism). The purpose is to help control the systemic hormonal imbalance caused by this overactivity in adult patients.

Q: Does Modrenal contain steroids?

Modrenal's active ingredient, Trilostane, is classified as a steroid synthesis inhibitor. This means its function is to block a key enzyme that the body uses to create certain steroid hormones, like cortisol. It is a synthetic chemical compound but does not itself replace the body's steroid hormones.

Q: Is Modrenal safe to use for older adults?

According to official prescribing information, this medicine is intended for use in the general adult population. Specific, separate safety data or restrictions for use solely in the older adult age group are not detailed in the available regulatory summaries.

Q: Is Modrenal safe for people with high blood pressure?

Clinical research associated with the medicine has examined the monitoring of systemic blood pressure as part of the measured outcomes during trials. Official regulatory documentation does not note pre-existing high blood pressure as a specific, mandatory restriction or contraindication for use.

Q: What are the signs of a severe allergic reaction to Modrenal?

Official safety labeling formally contraindicates the medicine for individuals with known hypersensitivity or allergy to its components. Regulatory sources note that rare, severe skin reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, have been documented.

Q: Why is it important to tell the doctor all medicines I take when prescribed Modrenal?

According to regulatory documents, disclosure of all current medicines is important due to potential drug interactions. Modrenal is advised against co-administration with certain agents, such as potassium-sparing diuretics, because the combination may increase the risk of hyperkalemia (elevated potassium levels).

Q: How new is Modrenal as a medicine?

Official research reviews and historical context indicate that the evidence base for Modrenal is considered largely historical. Furthermore, official sources note that the medicine's authorization for human use was revoked in major territories, which provides context on its history.

Q: Does Modrenal require special blood tests before or during treatment?

Regulatory summaries document that key endocrine markers such as cortisol levels and serum potassium levels were monitored during clinical research. Research indicates monitoring of these markers, which is consistent with the drug's action and the documented potential for adrenal insufficiency.

Q: Is weight gain a reported side effect of Modrenal?

Weight gain is not listed as one of the commonly reported adverse reactions or serious side effects in the official safety profile for the medicine. The official documents classify adverse reactions by frequency, and weight gain does not appear in those lists.

Q: Was Modrenal originally developed for a different purpose?

Historical clinical research has observed the medicine in contexts other than its primary current uses. Official documents indicate that the drug was previously evaluated in studies concerning postmenopausal breast cancer, where it was examined in combination with a corticosteroid.

How should Modrenal be stored and disposed of?

How to Store and Dispose of Modrenal

Storage and disposal of Modrenal (Trilostane hard capsules) must adhere strictly to the conditions documented in official regulatory labeling to ensure product integrity and proper pharmaceutical waste management.

Storage Requirements

Modrenal must be stored at a temperature below 25 C. The product must be kept in the original container or blister packaging, and the container must remain tightly closed to protect the capsules from moisture. This medication must also be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Modrenal capsules must not be thrown away with household waste or disposed of via wastewater. For correct pharmaceutical waste disposal that helps protect the environment, patients are instructed to ask a pharmacist for guidance on how to discard medicine no longer required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Modrenal found in:

A-Z Index: